AR003941A1 - Anticuerpos monoclonales humanos neutralizadores de hiv-1 - Google Patents

Anticuerpos monoclonales humanos neutralizadores de hiv-1

Info

Publication number
AR003941A1
AR003941A1 ARP960102232A AR10223296A AR003941A1 AR 003941 A1 AR003941 A1 AR 003941A1 AR P960102232 A ARP960102232 A AR P960102232A AR 10223296 A AR10223296 A AR 10223296A AR 003941 A1 AR003941 A1 AR 003941A1
Authority
AR
Argentina
Prior art keywords
antibodies
hiv
present
mixtures
cell lines
Prior art date
Application number
ARP960102232A
Other languages
English (en)
Original Assignee
Polymun Scient Immunbilogische Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1995/001481 external-priority patent/WO1996033219A1/en
Application filed by Polymun Scient Immunbilogische Forschung Gmbh filed Critical Polymun Scient Immunbilogische Forschung Gmbh
Publication of AR003941A1 publication Critical patent/AR003941A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención describe anticuerpos que pueden usarse para la fabricación de vacunas para la inmunización activa y/o pasiva de personas quenecesitan dicho tratamiento. La invención también proporciona anticuerpos monoclonaleshuma nos que son funcionalmente equivalentes a los anticuerposmencionados anteriormente producidos por una cualquiera de las líneas celulares CL1 a CL6 (depositadas en la Colección Europea de Cultivos de Células Animales(ECACC) en HPLS en PortonDown, Sal isbury, Reino Unido). La invención provee además fragmentos peptídicos capaces de inducir anticuerpos neutralizantescontra HIV y su aplicación como vacuna para inmunización activa. También es un objeto de la presente invenciónproporcionar líneas de células de CHO queproducen uno cualquiera de los anticuerpos descriptos y reivindicados en este documento. La invención se dirige adicionalmente a mezclas de dichosanticuerpos de la presente invención, así como aprocedimientos para usar anticuerpos individuales o mezclas de los mismos para la detección, prevencióny/o tratamiento terapéutico de infecciones por HIV-1 in vitro e in vivo.
ARP960102232A 1995-04-19 1996-04-18 Anticuerpos monoclonales humanos neutralizadores de hiv-1 AR003941A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/001481 WO1996033219A1 (en) 1995-04-19 1995-04-19 Monoclonal antibodies against hiv-1 and vaccines made thereof

Publications (1)

Publication Number Publication Date
AR003941A1 true AR003941A1 (es) 1998-09-30

Family

ID=23900329

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102232A AR003941A1 (es) 1995-04-19 1996-04-18 Anticuerpos monoclonales humanos neutralizadores de hiv-1

Country Status (2)

Country Link
US (1) US6268484B1 (es)
AR (1) AR003941A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
ES2272296T3 (es) * 1999-06-18 2007-05-01 Research Foundation Of State University Of New York Grupos de borrelia burgdorferi que producen la enfermedad de lyme en humanos.
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP4257688A1 (en) * 2020-12-21 2023-10-11 Kanglin Biotech (Hangzhou) Co., Ltd. Nucleic acid construct for aids gene therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761470A (en) 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5087557A (en) 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins

Also Published As

Publication number Publication date
US6268484B1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
ATE219105T1 (de) Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
AR003941A1 (es) Anticuerpos monoclonales humanos neutralizadores de hiv-1
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
ATE523224T1 (de) Verifizierung von läsionsmerkmalen mit strahlformen
ES2196008T3 (es) Vacuna del virus de la hepatitis e y procedimiento.
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ES2190799T3 (es) Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
DE69030383D1 (de) Impfstoff-Konjugate zur Behandlung von Vogelkrankheiten
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
DE60142684D1 (de) Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
RU2261105C1 (ru) Способ профилактики клещевого энцефалита
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
DE69707680D1 (de) Caprin arthritis-enzephalitis virus enthaltende vakzine und verwendung zur immunschutz gegen hiv-1 infektion

Legal Events

Date Code Title Description
FB Suspension of granting procedure